RCKT: Rocket Pharmaceuticals Inc P/S Multiple

Symbol and logo of brand Rocket Pharma (RCKT)

The P/S multiple dynamics highlight the efficiency of the complex genetic material logistics that support margins for Rocket Pharmaceuticals (RCKT). However, the absence of current revenue due to the research stage creates financial uncertainty. Patents for the treatment of rare pathologies serve as a defense, creating barriers for competitors. The latest reading currently stands at , which allows for an assessment of market expectations regarding the company's future sales.

RCKT: Rocket Pharmaceuticals, Inc. Price-to-Revenue Ratio 07/04/2022 - 11/13/2026

Analytical breakdowns for Rocket Pharmaceuticals Inc (RCKT)

- share price and consensus valuation forecast:
Price Performance Chart rocketpharma.com|RCKT - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Rocket Pharmaceuticals Inc|RCKT - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Rocket Pharmaceuticals|RCKT - Company Book Value|Market Cap to Net Assets Ratio rocketpharma.com|RCKT - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Rocket Pharmaceuticals|RCKT - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Rocket Corp|RCKT - Company Aggregate Debts|Debts to Book Value Rocket Pharmaceuticals Inc|RCKT - Company Long-Term Liabilities|Company Short-Term Debts Rocket Pharmaceuticals|Intermediate Liquidity Ratio rocketpharma.com
- earnings and valuation multiples information:
RCKT - Net Profit|Company Profit Forecast Rocket Pharmaceuticals|RCKT - P/E Multiple|Projected Price to Earnings Rocket Pharma|RCKT - PEG Multiple|EV/EBITDA Multiple Rocket Pharmaceuticals Inc|RCKT - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Rocket Pharmaceuticals|RCKT - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months rocketpharma.com|RCKT - Earnings per share growth in current year|Expected earnings per share trend next year Rocket Pharmaceuticals
- total revenue and sales volume data:
RCKT - Revenue and Sales Volume|Company Future Sales Volume rocketpharma.com|RCKT - Price-to-Revenue Ratio|Forward P/S Multiple Rocket Pharmaceuticals Inc
General company analysis:RCKT - rocketpharma.com
Signature product of Rocket Pharmaceuticals

The price-to-sales ratio reflects the proportion of market capitalization to revenue, where chart volatility is driven exclusively by price fluctuations against static reporting data. For Rocket Pharmaceuticals (RCKT), whose gene therapy developments are protected by humanitarian status and the stability of US regulations, analyzing this indicator allows for the timely identification of the risk of overpaying for the asset amid price growth.

Who Rocket Pharmaceuticals competes with

TEM (Tempus AI) - Market Capitalization-to-Revenue Ratio|P/S Multiple QGEN (Qiagen)|P/S Multiple Ionis Pharmaceuticals, Inc. IONS|RGEN - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio RNA (Avidity Corp)|CRISPR Therapeutics AG (CRSP) - Price-to-Revenue Ratio|Market Cap to Revenue genedx.com|RARE (Ultragenyx) - P/S Multiple|P/S Multiple Beam Therapeutics Inc|P/S Multiple SRPT|Market Cap to Revenue Twist Bioscience Corp TWST|P/S Multiple TXG (10x Genomics, Inc.)|intelliatx.com (NTLA) - Price to Sales|STOK: Market Cap to Revenue|BLFS - P/S Multiple|WVE (Wave Life Sciences Corp) - Market Cap to Revenue|MAZE: Market Cap to Sales Volume|SION (Sionna Therapeutics Inc) - P/S Multiple|primemedicine.com (PRME) - Price-to-Revenue Coefficient|P/S Multiple TSHA|Market Cap to Revenue uniQure NV QURE|P/S Multiple MGTX (MeiraGTx PLC)|P/S Multiple REGENXBIO Corp RGNX|SLDB - Price-to-Revenue Ratio|OCGN: Price-to-Revenue Ratio|PacBio (PACB) - Price-to-Revenue Ratio|BNTC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Design Pharma|FDMT: Market Capitalization-to-Revenue Ratio|P/S Multiple LXEO|Market Cap to Revenue korrobio.com KRRO|Price-to-Revenue Ratio Editas Medicine EDIT|P/S Multiple Silence Therapeutics PLC SLN|PRQR: Market Cap to Revenue|Codexis, Inc. - Market Cap to Sales Volume|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio Metagenomi|Market Cap to Revenue Ratio DTIL (precisionbiosciences.com)|P/S Multiple GBIO|P/S Multiple Boundless Bio Inc (BOLD)|Price-to-Revenue Ratio Exicure XCUR|Market Capitalization-to-Revenue Ratio IMNN|PHIO - Price-to-Revenue Ratio|Price to Sales Mustang Bio, Inc.|RNAZ: P/S Multiple|Market Cap to Revenue Bionano Genomics|Price-to-Revenue Ratio Applied DNA Sciences|P/S Multiple bluebirdbio.com|P/S Multiple IPA|OMGA - Price to Sales|Singular Genomics Systems Inc - Market Cap to Revenue|Market Cap to Sales Volume RGLS (Regulus)|SYRS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio TBIO (telesisbio.com)|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Price-to-Sales Ratio UBX (Unity Biotechnology Inc.)